Tissue factor and Toll-like receptor (TLR)4 in hyperglycaemia-hyperinsulinaemia

Anamika Singh; Guenther Boden; A. Koneti Rao

doi:10.1160/TH14-10-0884

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2015; 113(04): 750-758
DOI: 10.1160/TH14-10-0884

Coagulation and Fibrinolysis

Schattauer GmbH

Tissue factor and Toll-like receptor (TLR)4 in hyperglycaemia-hyperinsulinaemia

Effects in healthy subjects, and type 1 and type 2 diabetes mellitus

Anamika Singh

¹Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA

,

Guenther Boden

²Division of Endocrinology/Diabetes/Metabolism and the Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA

,

A. Koneti Rao

²Division of Endocrinology/Diabetes/Metabolism and the Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA

³Division of Hematology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA

› Institutsangaben

Abstract

Summary

Diabetes mellitus (DM) patients have an increased incidence of cardiovascular events. Blood tissue factor-procoagulant activity (TF-PCA), the initiating mechanism for blood coagulation, is elevated in DM. We have shown that hyperglycaemia (HG), hyperinsulinaemia (HI) and combined HG+HI (induced using 24-hour infusion clamps) increases TF-PCA in healthy and type 2 DM (T2DM) subjects, but not in type 1 DM (T1DM) subjects. The mechanisms for this are unknown. DM patients have elevated plasma lipopolysaccharide (LPS), a toll-like receptor (TLR) 4 ligand. We postulated that TLR4 plays a role in modulating TF levels. We studied the effect of HG+HI on TLR4 and TF-PCA in vivo during 24-hour HG+HI infusion clamps in healthy subjects, and T1DM and T2DM subjects, and in vitro in blood. In vivo, in healthy subjects, 24-hour HG + HI infusion increased TLR4 six-fold, which correlated with TF-PCA (r=0.91, p<0.0001). T2DM patients showed smaller increases in both. In T1DM subjects, TLR4 declined (50%, p<0.05) and correlated with TF-PCA (r=0.55; p<0.05). In vitro, HG (200 mg/dl added glucose) and HI (1-100 nM added insulin) increased TF-PCA in healthy subjects (˜2-fold, 2-4 hours). Insulin inhibited by ~30% LPSinduced increase in TF-PCA and high glucose reversed it. TLR4 levels paralleled TF-PCA (r=0.71, p<0.0001); HG and HI increased TLR4 and insulin inhibited LPS-induced TLR4 increase. This is first evidence that even in healthy subjects, HG of short duration increases TLR4 and TFPCA, key players in inflammation and thrombosis. TLR4-TF interplay is strikingly different in non-diabetic, T1DM and T2DM subjects.

Keywords

Diabetes mellitus - hyperglycaemia - hyperinsulinaemia - tissue factor - Toll-like receptor-4

Volltext

Referenzen

References
1 Grundy SM, Howard B, Smith Jr. S. et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-2239.
2 Capes SE, Hunt D, Malmberg K. et al. Stress hyperglycaaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-778.
3 Umpierrez GE, Isaacs SD, Bazargan N. et al. Hyperglycaemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87: 978-982.
4 Falciglia M, Freyberg RW, Almenoff PL. et al. Hyperglycaemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009; 37: 3001-3009.
5 Kosiborod M, Rathore SS, Inzucchi SE. et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005; 111: 3078-3086.
6 Targher G, Chonchol M, Zoppini G. et al. Hemostatic disorders in type 1 diabetes mellitus. Saemin Thromb Hemost 2011; 37: 58-65.
7 Carmassi F, Morale M, Puccetti R. et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67: 643-654.
8 Bogdanov VY, Osterud B. Cardiovascular complications of diabetes mellitus: The Tissue Factor perspective. Thromb Res 2010; 125: 112-118.
9 Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 07: 260-273.
10 Kakouros N, Rade JJ, Kourliouros A. et al. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol 2011; 2011742719.
11 Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 2000; 10: 139-143.
12 Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 2006; 32: 5-10.
13 Wilcox JN, Smith KM, Schwartz SM. et al. Localisation of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
14 Giesen PL, Rauch U, Bohrmann B. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
15 Key NS, Slungaard A, Dandelet L. et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-4223.
16 Chou J, Mackman N, Merrill-Skoloff G. et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-3197.
17 Sambola A, Osende J, Hathcock J. et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-977.
18 Boden G, Vaidyula VR, Homko C. et al. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007; 92: 4352-4358.
19 Singh A, Boden G, Homko C. et al. Whole-Blood Tissue Factor Procoagulant Activity Is Elevated in Type 1 Diabetes: Effects of hyperglycaemia and hyperinsulinaemia. Diabetes Care 2012; 35: 1322-1327.
20 Vaidyula VR, Rao AK, Mozzoli M. et al. Effects of hyperglycaemia and hyperinsulinaemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55: 202-208.
21 Devaraj S, Dasu MR, Park SH. et al. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009; 52: 1665-1668.
22 Creely SJ, McTernan PG, Kusminski CM. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E740-E747.
23 Al-Attas OS, Al-Daghri NM, Al-Rubeaan K. et al. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 2009; 820.
24 Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 01: 135-145.
25 Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 04: 499-511.
26 Bruserud O. Bidirectional crosstalk between platelets and monocytes initiated by Toll-like receptor: an important step in the early defense against fungal infections?. Platelets 2013; 24: 85-97.
27 Kim JJ, Sears DD. TLR4 and Insulin Resistance. Gastroenterol Res Pract 2010; 2010.
28 Jain SK, Rains JL. Toll-like receptor-4 and vascular inflammation in diabetes: editorial. Cytokine 2011; 55: 446-447.
29 Shi H, Kokoeva MV, Inouye K. et al. TLR4 links innate immunity and fatty acidinduced insulin resistance. J Clin Invest 2006; 116: 3015-3025.
30 Kolek MJ, Carlquist JF, Muhlestein JB. et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148: 1034-1040.
31 Gerrits AJ, Koekman CA, Yildirim C. et al. Insulin inhibits tissue factor expression in monocytes. J Thromb Haemost 2009; 07: 198-205.
32 Ferreira IA, Mocking AI, Feijge MA. et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26: 417-422.
33 Gerrits AJ, Koekman CA, van Haeften TW. et al. Increased tissue factor expression in diabetes mellitus type 2 monocytes caused by insulin resistance. J Thromb Haemost 2011; 09: 873-875.
34 Stark RJ, Aghakasiri N, Rumbaut RE. Platelet-derived Toll-like receptor 4 (Tlr-4) is sufficient to promote microvascular thrombosis in endotoxaemia. PLoS One 2012; 07: e41254.
35 Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycaemia and hyperinsulinaemia in healthy subjects. Platelets 2006; 17: 577-585.
36 Dasu MR, Devaraj S, Zhao L. et al. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008; 57: 3090-3098.
37 Owens 3rd AP, Passam FH, Antoniak S. et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolaemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012; 122: 558-568.
38 Frantz S, Ertl G, Bauersachs J. Toll-like receptor signaling in the ischaemic heart. Front Biosci 2008; 135772-135779.
39 Zhang Y, Peng T, Zhu H. et al. Prevention of hyperglycaemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J Transl Med 2010; 8133.
40 Devaraj S, Dasu MR, Rockwood J. et al. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008; 93: 578-583.
41 Ghanim H, Mohanty P, Deopurkar R. et al. Acute modulation of toll-like receptors by insulin. Diabetes Care 2008; 31: 1827-1831.
42 Kanhaiya NKA, Agrawal NK, Gupta SK. et al. Differential expression of toll like receptor 4 in type 2 diabetic patients with impaired wound healing. J Diabetes Metab 2013; 04: 260.
43 Zhu W, Li W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD 36. Blood 2012; 119: 6136-6144.
44 Ichikawa K, Yoshinari M, Iwase M. et al. Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis 1998; 136: 281-287.